Friday, September 25, 2026
← Back to archivePolicy
Policy•Endpoints News•Sep 24, 2026
Elevar wins first FDA approval with second-line drug for bile duct cancer
background ▾
- •Lyrfigtus becomes Elevar's first FDA-approved drug, validating the company's pipeline and providing initial commercial revenue
- •Second-line positioning in a rare cancer with limited therapeutic alternatives suggests potential for rapid uptake and favorable reimbursement, though market size remains modest at ~8,000 diagnosed cases annually
- •Monitor for Phase 3 data publication, payer coverage decisions, and potential label expansions to first-line or other cancer indications
Elevar TherapeuticsLyrfigtus
→ Read original articlePolicy•KFF•Sep 24, 2026
Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
background ▾
- •Nearly all U.S. states now have at least one active Section 1115 waiver, demonstrating widespread use of this regulatory flexibility tool for Medicaid program modifications
- •Multiple states are implementing Medicaid work requirements ahead of the federally mandated January 1, 2027 deadline, signaling a policy shift that will affect eligibility and enrollment
- •Monitor state-level waiver amendments and work requirement implementations, as these will directly impact Medicaid enrollment levels and patient access to covered drugs in different regions
Policy•KFF•Sep 24, 2026
Abortion on the 2026 Ballot: The Evolving Landscape of State Abortion Initiatives
background ▾
- •This is a healthcare policy analysis piece focused on abortion ballot initiatives, not a pharmaceutical industry development—it falls outside core pharma/biotech news coverage
Policy•KFF•Sep 24, 2026
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive
background ▾
- •TrumpRx prices for brand-name drugs are roughly as likely to be above international reference prices as below them, contradicting claims of consistently lowest-in-world pricing
- •Price comparison is complicated by methodological differences: international 'publicly listed prices' often represent government negotiated rates, not consumer out-of-pocket costs, limiting the policy's transparency claims
- •Monitor whether this analysis prompts congressional scrutiny of TrumpRx's actual savings impact and whether manufacturers adjust pricing strategy in response to public pressure
Policy•Fierce Biotech•Sep 24, 2026
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
background ▾
- •Overton explicitly affirmed FDA-approved vaccines and mifepristone are safe and effective, but stopped short of directly contradicting Trump's medical misinformation, suggesting potential tension between statutory FDA obligations and political loyalty if confirmed.
- •Senators revealed Overton held a more influential role in the MMR vaccine-splitting executive order than she acknowledged, raising questions about her actual policy influence and independence.
- •Watch for the HELP Committee vote and full Senate confirmation vote; any conditions or commitments Overton makes regarding FDA independence from presidential pressure could reshape regulatory predictability for vaccine policy, drug approvals, and reproductive health products.
mifepristoneMMR vaccineTylenol
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 25, 2026
Indivior ends PAM drug collab with Addex ahead of Supernus merger
background ▾
- •Indivior is systematically divesting early-stage and non-core programs (this PAM collaboration and the Alar buprenorphine prodrug) as part of pre-merger R&D rationalization, signaling portfolio focus on near-term revenue drivers like Sublocade
- •Addex now controls one of the broadest GABAB PAM portfolios in the field but faces uncertainty in advancing programs independently after losing a major partner, particularly given J&J's recent discontinuation of a similar compound
IndiviorAddex TherapeuticsSupernusADX71441Sublocadebuprenorphine
→ Read original articleMarket Access•Fierce Biotech•Sep 24, 2026
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
background ▾
- •FDA advisory committee voted positively on Galleri across all three measures (7-2 on clinical utility, unanimous on safety, 6-4 on efficacy), advancing the first multi-cancer early detection blood test toward potential U.S. pre-market approval
- •The February 2024 NHS-Galleri trial missed its primary endpoint for statistically significant reduction in stage III-IV cancers, creating credibility risk that the advisory committee nonetheless navigated
- •Final FDA decision expected within months; watch for approval decision and how any conditional approval language may affect current commercial availability through Everlywell and Hims & Hers partnerships
GrailEverlywellHims & HersGalleri
→ Read original articleMarket Access•Fierce Biotech•Sep 24, 2026
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
background ▾
- •Roche is substantially investing in allosteric modulation as a novel approach to traditionally difficult CVRM targets, signaling confidence in Atavistik's AMPS platform as a differentiated discovery engine
- •This partnership underscores Roche's deliberate pivot toward CVRM as a core strategic pillar, following recent major acquisitions (Carmot Therapeutics for $2.7B, 89bio for $3.5B) and partnerships (Alnylam, zilebesiran)
- •Watch for clinical readouts from Atavistik's internal pipeline (ATV-1601 in phase 1/2 for HHT; JAK2 inhibitors for myeloproliferative neoplasms) and Roche's ability to translate allosteric discoveries into regulated candidates in CVRM indications
RocheAtavistik BioRA Capital ManagementATV-1601zilebesiranAvastin
→ Read original articleMarket Access•Fierce Biotech•Sep 25, 2026
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
background ▾
- •Novo is betting $1.33B on Nanexa's inorganic coating technology (PharmaShell) to create subcutaneous depots that enable monthly/quarterly dosing of GLP-1 and other peptides—a direct response to competitive long-acting injectable programs from Pfizer and Eli Lilly.
- •Novo's chief scientific officer flagged tolerability and efficacy concerns with Pfizer's once-monthly GLP-1 candidate and indicated Novo will advance multiple first-in-human programs this year, suggesting meaningful technical hurdles remain unsolved.
- •Watch for Novo's clinical readouts from at least three to four once-monthly GLP-1 candidates over the next 12 months, and monitor whether Nanexa's platform delivers the tolerability profile Novo deems necessary for commercial viability in the high-stakes obesity market.
Novo NordiskNanexaPfizerGLP-1 receptor agonists
→ Read original articleMarket Access•Fierce Biotech•Sep 25, 2026
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
background ▾
- •Genentech's $1.5B bispecific deal signals major pharma's aggressive pursuit of modality leaders and platform companies to derisk and accelerate pipeline expansion, particularly in oncology where multi-target mechanisms are seen as critical for durable response.
- •Earendil has raised >$5B in total deal value within 18 months (Sanofi, Genentech, WuXi XDC, and Series B capital), validating the commercial value of AI-enabled antibody discovery platforms and establishing it as a tier-one discovery partner.
- •Monitor: clinical data from Earendil's T-cell engagers (GUCY2C/DLL3, CEACAM5/CDH17) and ADCs; whether Genentech advances candidates to IND; and whether this deal model becomes standard for oncology pipeline replenishment among top-10 pharma.
RocheGenentechEarendil Labsbispecific antibodiesT-cell engagersantibody-drug conjugates
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 24, 2026
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
background ▾
- •Phase 2 primary endpoint missed with 0.26 effect size (vs. expected 0.35–0.4) and p-value of 0.0603—just above the 0.05 significance threshold—characterized by analysts as a 'near miss' but sufficient to justify phase 3 progression.
- •Remlifanserin demonstrated superior safety profile over Nuplazid with no QT prolongation signal, no motor impairment, and similar adverse event rates to placebo, addressing key liabilities of Acadia's existing Alzheimer's psychosis therapy.
- •Acadia plans phase 3 with enriched population criteria targeting modestly higher baseline psychosis; post-hoc analysis suggests enrichment could boost effect size to 0.33—watch for phase 3 enrollment speed and efficacy signals in high-risk Alzheimer's psychosis patients.
Acadia PharmaceuticalsremlifanserinACP-204Nuplazid
→ Read original articleClinical Trials•Endpoints News•Sep 24, 2026
Merck’s return to ophthalmology snags first success
background ▾
- •EyeBio program demonstrates efficacy in clinical trials, validating Merck's $1.3B acquisition investment and commitment to rebuilding its ophthalmology franchise
- •Analyst concerns about safety profile create uncertainty around regulatory pathway and commercial viability despite efficacy success
- •Monitor upcoming safety data readouts, regulatory submissions, and whether EyeBio programs advance to Phase 3 or face development delays
MerckEyeBio
→ Read original articleClinical Trials•Endpoints News•Sep 24, 2026
Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
background ▾
- •One-year durability data in stiff person syndrome support regulatory submission for Kyverna's CAR-T therapy in a rare autoimmune indication
- •CAR-T cell therapies in autoimmunity remain an emerging therapeutic category with limited precedent in FDA approval and reimbursement
- •Monitor FDA review timeline and post-approval commercialization strategy given the ultra-rare patient population (~6,000 patients)
Kyverna Therapeutics
→ Read original article